Andrew Reardon, Chief Legal Officer & Secretary, on August 03, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,444,951. Following the Form 4 filing with the SEC, Reardon has control over a total of 41,514 common shares of the company, with 41,514 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/xslF345X05/edgardoc.xml